Best percentage change from baseline in target lesion size in patients with cHL receiving therapy with PI3Kδ inhibitor INCB040093 alone or in combination with JAK1 inhibitor itacitinib. Included are patients with data available for best percentage change from baseline in target lesion size (n = 37 [monotherapy, n = 17; combination therapy, n = 20]). The upper dotted line corresponds to criteria for PD (at least 50% increase) and lower to PR (at least 50% decrease). PD indicates PD or relapsed disease (after CR). Patients with ¹⁸F-FDG-avid lymphoma who were PET-positive at baseline could achieve a CR without complete resolution of the target lesion if the lesion became PET-negative per the Revised Response Criteria for Malignant Lymphoma.²³  *Best percentage change from baseline in target lesion size >100%. †Patients who discontinued INCB040093 monotherapy and re-enrolled into the study to receive combination therapy. ‡Patients who had previously received INCB040093 monotherapy.